Enhanced thrombogenesis but not platelet activation is associated with transcatheter closure of patent foramen ovale in patients with cryptogenic stroke

Stroke

Volumn 38, Issue 1, 2007, Pages 100-104

  Bédard, Elisabeth ^a   Rodés Cabau, Josep ^a   Houde, Christine ^b   MacKey, Ariane ^b   Rivest, Donald ^c   Cloutier, Stéphanie ^b   Noël, Martin ^a   Marrero, Alier ^b   Côté, Jean Marc ^b   Chetaille, Philippe ^b   Delisle, George ^b   Leblanc, Marie Helene ^a   Bertrand, Olivier F ^a  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Hotel Dieu de Levis Hospital   (Canada)

Author keywords

Coagulation; Cryptogenic stroke; Patent foramen ovale; Platelets; Transcatheter closure

Indexed keywords

ACETYLSALICYLIC ACID; BIOCHEMICAL MARKER; CD40 LIGAND; HEPARIN; PADGEM PROTEIN; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HEMOSTASIS; HUMAN; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STROKE; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOGENESIS;

ADULT; ANTICOAGULANTS; ANTITHROMBIN III; BIOLOGICAL MARKERS; BLOOD COAGULATION; CARDIAC SURGICAL PROCEDURES; CD40 LIGAND; CEREBROVASCULAR ACCIDENT; FEMALE; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; PROTHROMBIN; THROMBOSIS; TIME FACTORS;

EID: 33845923816     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000251712.55322.69     Document Type: Article

References (34)

1. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000;55:1172-1179.
2. Meier B, Lock J. Contemporary management of patent foramen ovale. Circulation. 2003;107:5-9.
3. Martín F, Sánchez PL, Doherty E, Colon-Hernandez PJ, Delgado G, Inglessis I, Scott N, Hung J, King ME, Buonanno F, Demirjian Z, de Moor M, Palacios IF. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation. 2002;106:1121-1126.
4. Windecker S, Wahl A, Chatterjee T, Garachemani A, Eberli F, Seiler C, Meier B. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation. 2000;101:893-898.
5. Braun M, Fassbender D, Schoen SP, Haass M, Schraeder R, Scholtz W, Strasser RH. Transcatheter closure of patent foramen ovale in patients with cerebral ischemia. J Am Coll Cardiol. 2002;39:2019-2025.
6. Braun M, Gliech V, Boscheri A, Schoen S, Gahn G, Reichmann H, Haass M, Schraeder R, Strasser RH. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J. 2004;25:424-430.
7. Windecker S, Wahl A, Nedeltchev K, Arnold M, Schwerzmann M, Seiler C, Mattle HP, Meier B. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol. 2004;44:750-758.
8. Beitzke A, Schuchlenz H, Gamillscheg A, Stein J, Wendelin G. Catheter closure of the persistent foramen ovale: mid-term results in 162 patients. J Interven Cardiol. 2001;14:223-230.
9. Wahl A, Meier B, Haxel B, Nedeltchev K, Arnold M, Eicher E, Sturzenegger M Seiler C, Mattle HP, Windecker S. Prognosis after percutaneous closure of patent foramen ovale for paradoxical embolism. Neurology. 2001;57:1330-1332.
10. Khositseh A, Cabalka AK, Sweeney JP, Fortuin FD, Reeder GS, Connolly HM, Hagler DJ. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism. Mayo Clin Proc. 2004;79:15-20.
11. Spies C, Strasheim R, Timmermanns I, Schraeder R. Patent foramen ovale closure in patients with cryptogenic thrombo-embolic events using the Cardia PFO occluder. Eur Heart J. 2006;27:365-371.
12. Onorato E, Melzi G, Casilli F, Pedon L, Rigatelli G, Carrozza A, Maiolino P, Zanchetta M, Morandi E, Angeli S, Anzola GP. Patent foramen ovale with paradoxical embolism: mid-term results of transcatheter closure in 256 patients. J Interven Cardiol. 2003;16:43-50.
13. Sievert H, Horvath K, Zadan E, Krumsdorf U, Fach A, Merle H, Scherer D, Schrader R, Spies H, Nowak B, Libmann-Jensen H. Patent foramen ovale closure in patients with transient ischemia attack/stroke. J Interven Cardiol. 2001;14:261-266.
14. Fijnheer R, Frijns CJM, Korteweg J, Rommes H, Peters JH, Sixma JJ. The origin of P-selectin as a circulating plasma protein. Thromb Haemost. 1997;76:1086-1089.
15. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-1111.
16. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/prothombin fragment 1+2 and thrombin/antithrombin complex. Blood. 1982;59:1086-1097.
17. Han YM, Gu X, Titus JL, Rickers C, Bass JL, Urness M, Amplatz K. New self-expanding patent foramen ovale occlusion device. Cathet Cardiovasc Interven. 1999;47:370-376.
18. Cenni E, Ciapetti G, Cervellati M, Cavedagna D, Falsone G, Gamberini S, Pizzoferrato A. Activation of the plasma coagulation system induced by some biomaterials. J Biomed Mater Res. 1996;31:145-148.
19. Hong J, Azens A, Ekdahl KN, Granqvist CG, Nilsson B. Material-specific thrombin generation following contact between metal surfaces and whole blood. Biomaterials. 2005;26:1397-1403.
20. Rodés-Cabau J, Palacios A, Palacio C, Girona J, Galve E, Evangelista A, Casaldaliga J, Albert D, Pico M, Soler-Soler J. Assessment of the markers of platelet and coagulation activation following transcatheter closure of atrial septal defects. Int J Cardiol. 2005;98:107-112.
21. Pernerstorfer T, Eichler HG, Stohlawetz P, Speiser W, Jilma B. Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand factor levels in healthy men. Atherosclerosis. 2001;155:389-393.
22. Pernerstorfer T, Stohlawetz P, Stummvoll G, Kapiotis S, Szekeres T, Eichler HG, Jilma B. Low-dose aspirin does not lower in vivo platelet activation in healthy smokers. Br J Haematol. 1998;102:1229-1231.
23. Klinkhardt U, Bauersachs R, Adams J, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther. 2003;73:232-241.
24. Serebruany V, Cummings C, Malinin A, Steinbul S, Gurbel P. Uniform platelet activation exists before coronary stent implantation despite aspirin therapy. Am Heart J. 2001;142:611-616.
25. Sherman JM, Hagler DJ, Cetta F. Thrombosis after septal closure device placement: a review of the current literature. Cathet Cardiovasc Interven. 2004;63:486-489.
26. Krumsdorf U, Ostermayer S, Billinger K, Trepels T, Zadan E, Horvath K, Sievert H. Incidence and clinical course of thrombus formation on atrial septal defect and patent foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol. 2004;43:302-309.
27. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke. 2006;37:577-617.
28. Anzola GP, Morandi E, Casilli F, Onorato E. Does transcatheter closure of patent foramen ovale really 'shut the door?' a prospective study with transcranial Doppler. Stroke. 2004;35:2140-2144.
29. Tan KT, Lip GY. Atrial fibrillation: should we target platelets or the coagulation pathway? Cardiol Electrophysiol Rev. 2003;7:370-371.
30. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-1912.
31. Cramer SC, Rordorf G, Maki JH, Kramer LA, Grotta JC, Burgin WS, Hinchey JA, Benesch C, Furie KL, Lutsep HL, Kelly E, Longstreth WT. Increased pelvic vein thrombi in cryptogenic stroke: results of the paradoxical emboli from large veins in ischemic stroke (PELVIS) study. Stroke. 2004;35:46-50.
32. Rigatelli G, Roncon L, Braggion G, Giordan M, Cardioli P, Zonzin P, Chinaglia M. Deep venous thrombosis before patent foramen ovale closure. Am J Med. 2006;119:97-98.
33. Bincardi M, Cimminiello C, Toschi V, Schiavina G, Regalia F, Carola F, Bonfardeci C. TAT, F1+2, and D-dimer levels in patients after coronary angiography with nonionic or ionic contrast media or after cardiac catheterization. Semin Thromb Hemost. 1996;22:61-65.
34. Hafner G, Schinzel H, Ehrenthal W, Wagner C, Konheiser U, Lotz J, Kohler H, Prellwitz WW. Influence of blood sampling from venipunctures and catheter systems on serial determinations of prothrombin activation fragment 1+2 and thrombin-antithrombin III complex. Ann Hematol. 1993;67:121-125.